PSTV Plus Therapeutics
- 1.6650
- +0.0650+4.06%
Plus Therapeutics News
Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Milestone Pharmaceuticals (MIST)
Buy Rating Affirmed for Plus Therapeutics Amid Strong Financials and Promising Clinical Trials
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV), Ambrx Biopharma (AMAM) and Marinus (MRNS)
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV), Beyond Air (XAIR) and Ovid Therapeutics (OVID)
Analysts Conflicted on These Healthcare Names: Geron (GERN), Silk Road Medical (SILK) and Plus Therapeutics (PSTV)
Promising Clinical Developments Drive Buy Rating for Plus Therapeutics: Analysis of Recent Trials and Future Prospects
JonesTrading Sticks to Its Buy Rating for Plus Therapeutics (PSTV)
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Plus Therapeutics (PSTV)
HC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Maintains $8 Price Target
Plus Therapeutics Analyst Ratings
H.C. Wainwright Keeps Their Buy Rating on Plus Therapeutics (PSTV)
Plus Therapeutics Analyst Ratings
JonesTrading Keeps Their Buy Rating on Plus Therapeutics (PSTV)
HC Wainwright Adjusts Price Target on Plus Therapeutics to $8 From $3.50, Maintains Buy Rating
Maxim Adjusts Price Target on Plus Therapeutics to $12 From $30, Maintains Buy Rating
Maxim Group Maintains Buy on Plus Therapeutics, Lowers Price Target to $12
Analysts Are Bullish on Top Healthcare Stocks: Plus Therapeutics (PSTV), Biomea Fusion (BMEA)
JonesTrading Sticks to Their Buy Rating for Plus Therapeutics (PSTV)
Analysis
Price Target
No Data
